Stockscreener 앱 받기
2.40
1.84%
-0.05
시간 외 거래:
2.40
전일 마감가:
$2.45
열려 있는:
$2.45
하루 거래량:
863.66K
Relative Volume:
0.51
시가총액:
$347.23M
수익:
$288.95M
순이익/손실:
$-119.03M
주가수익비율:
-2.6652
EPS:
-0.9005
순현금흐름:
$60.67M
1주 성능:
-6.42%
1개월 성능:
-10.59%
6개월 성능:
-23.41%
1년 성능:
-73.01%
1일 변동 폭
$2.345
$2.45
1주일 범위
$2.345
$2.585
52주 변동 폭
$1.665
$9.60
마라바이 라이프 Stock (MRVI) Company Profile
명칭
Maravai Lifesciences Holdings Inc
전화
(858) 546-0004
주소
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO
MRVI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRVI
Maravai Lifesciences Holdings Inc
|
2.40 | 371.82M | 288.95M | -119.03M | 60.67M | -0.9005 |
|
VRTX
Vertex Pharmaceuticals Inc
|
388.94 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.38 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.64 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
677.32 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
308.63 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
마라바이 라이프 Stock (MRVI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-12-19 | 개시 | Guggenheim | Neutral |
| 2024-12-05 | 다운그레이드 | Goldman | Neutral → Sell |
| 2024-11-14 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-08 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-08-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-04-10 | 개시 | Craig Hallum | Buy |
| 2023-12-12 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-08-08 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-05-23 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-05-09 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-01-05 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-12-14 | 개시 | Deutsche Bank | Buy |
| 2022-12-07 | 개시 | RBC Capital Mkts | Outperform |
| 2022-11-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2021-08-05 | 재개 | Credit Suisse | Outperform |
| 2020-12-16 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-12-15 | 개시 | BofA Securities | Buy |
| 2020-12-15 | 개시 | Credit Suisse | Outperform |
| 2020-12-15 | 개시 | Goldman | Buy |
| 2020-12-15 | 개시 | Jefferies | Buy |
| 2020-12-15 | 개시 | Robert W. Baird | Outperform |
| 2020-12-15 | 개시 | Stifel | Buy |
| 2020-12-15 | 개시 | William Blair | Outperform |
| 2020-12-14 | 개시 | UBS | Buy |
모두보기
마라바이 라이프 주식(MRVI)의 최신 뉴스
Bullish Divergence Spotted in Maravai LifeSciences Holdings Inc. MomentumMarket Activity Summary & Verified Momentum Stock Watchlist - beatles.ru
Is Maravai LifeSciences Holdings Inc. meeting your algorithmic filter criteria2025 EndofYear Setup & Trade Opportunity Analysis Reports - Newser
Risk adjusted return profile for Maravai LifeSciences Holdings Inc. analyzedGap Down & Weekly Watchlist for Hot Stocks - Newser
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q2 2025 Earnings Call Transcript - MSN
Will Maravai LifeSciences Holdings Inc. see short term momentumMarket Movers & AI Enhanced Execution Alerts - Newser
Short interest data insights for Maravai LifeSciences Holdings Inc.July 2025 Analyst Calls & Scalable Portfolio Growth Ideas - Newser
Maravai LifeSciences Holdings, Inc. (MRVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Maravai LifeSciences Holdings Inc. stock trend outlook and recovery pathQuarterly Trade Summary & High Yield Stock Recommendations - Newser
Should you hold or exit Maravai LifeSciences Holdings Inc. nowAnalyst Downgrade & Smart Allocation Stock Tips - Newser
Earnings visualization tools for Maravai LifeSciences Holdings Inc.Weekly Profit Summary & Weekly High Potential Stock Alerts - Newser
Maravai LifeSciences (MRVI) Undergoes Leadership Overhaul Amid Transition - MSN
How to forecast Maravai LifeSciences Holdings Inc. trends using time seriesMarket Movers & AI Driven Stock Reports - Newser
Is Maravai LifeSciences Holdings Inc. trending in predictive chart models2025 Top Gainers & Reliable Volume Spike Alerts - Newser
Maravai LifeSciences Holdings Inc. stock daily chart insights2025 Year in Review & Fast Exit and Entry Strategy Plans - Newser
Has Maravai LifeSciences Holdings Inc. found a price floorJuly 2025 Review & Accurate Intraday Trade Tips - Newser
How to use a screener to detect Maravai LifeSciences Holdings Inc. breakouts - Newser
Can you recover from losses in Maravai LifeSciences Holdings Inc.Quarterly Growth Report & Verified Short-Term Trading Plans - Newser
What candlestick patterns are forming on Maravai LifeSciences Holdings Inc.Weekly Market Report & Reliable Price Breakout Signals - Newser
Sentiment analysis tools applied to Maravai LifeSciences Holdings Inc.Recession Risk & Low Drawdown Investment Ideas - Newser
Maravai LifeSciences Announces Restructuring Amid Revenue Decline - TipRanks
Live market analysis of Maravai LifeSciences Holdings Inc.Profit Target & Verified Stock Trade Ideas - Newser
Is Maravai LifeSciences Holdings Inc. Forming a Bottom PatternTrade Entry Summary & Community Trade Idea Sharing Platform - thegnnews.com
Published on: 2025-08-15 03:37:48 - thegnnews.com
Bronstein, Gewirtz & Grossman, LLC Encourages Maravai LifeSciences Holdings, Inc. (MRVI) Investors to Inquire about Securities Investigation - ACCESS Newswire
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Just Reported Earnings, And Analysts Cut Their Target Price - simplywall.st
Maravai LifeSciences Holdings Second Quarter 2025 Earnings: EPS Misses Expectations - Yahoo Finance
3 Promising Penny Stocks With At Least $200M Market Cap - simplywall.st
Maravai LifeSciences (NASDAQ:MRVI) Price Target Cut to $5.00 by Analysts at Royal Bank Of Canada - Defense World
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Shares Acquired by XTX Topco Ltd - Defense World
Maravai Lifesciences Holdings (MRVI) Maintains Buy Rating at RBC Capital with $5.00 Target Price - AInvest
Guggenheim Maintains Hold Rating on Maravai Lifesciences Holdings, Analyst Consensus Sees 85.92% Upside - AInvest
Maravai LifeSciences Announces Cost-Cutting Plan - 富途牛牛
RBC Capital Maintains MRVI Rating, Lowers Price Target | MRVI St - GuruFocus
Maravai LifeScience stock maintains Buy rating at Stifel despite guidance withdrawal - Investing.com Nigeria
Maravai LifeScience stock maintains Buy rating at Stifel despite guidance withdrawal By Investing.com - Investing.com South Africa
Maravai: RBC Capital Keeps Outperform, Cuts PT to $5 from $7. - AInvest
Maravai Lifesciences Announces Major Organizational Restructuring - MSN
Maravai (MRVI) Surges 27% on Restructuring Hopes and Earnings Drama: Is This a Short-Term Bounce or a Structural Turnaround? - AInvest
Craig-Hallum Keeps Their Buy Rating on Maravai Lifesciences Holdings (MRVI) - The Globe and Mail
Deutsche Bank Adjusts Maravai Lifesciences Price Target to $4.50 From $5, Maintains Buy Rating - MarketScreener
Maravai signals $50M annualized cost reduction plan as leadership targets positive EBITDA in 2026 - MSN
Maravai LifeSciences Q2 2025 Earnings Call Transcript - MarketBeat
Maravai LifeSciences Holdings Inc (MRVI) Q2 2025 Earnings Call Highlights: Navigating ... - Yahoo Finance
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q2 Loss, Lags Revenue Estimates - MSN
Maravai LifeSciences Holdings Inc (MRVI) Q2 2025 Earnings Call Highlights: Navigating ... By GuruFocus - Investing.com Canada
Maravai Lifesciences Holdings Maintains Buy Rating with $4.25 Price Target - AInvest
Maravai LifeSciences' Q2 2025: Key Contradictions in Revenue Dynamics and Strategic Outlook - AInvest
Maravai LifeSciences: Navigating Restructuring and Strategic Levers for Long-Term Value Creation - AInvest
Maravai LifeSciences Reports $50M Annualized Cost Reduction Plan, Targets Positive EBITDA by 2026 - AInvest
Maravai LifeSciences Holdings, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:MRVI) - Seeking Alpha
Transcript : Maravai LifeSciences Holdings, Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
마라바이 라이프 (MRVI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.34%
0.52%
자본화:
|
볼륨(24시간):